SeQuent Scientific
Viyash Scientific Limited (formerly SeQuent Scientific) is an Indian integrated pharmaceutical enterprise operating four verticals — API, Human Health formulations, Animal Health, and CDMO services — across 150+ countries, serving global pharmaceutical manufacturers from 15+ manufacturing facilities in India and abroad.
- Company typePublic
- Founded1985
- HeadquartersBangalore, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What SeQuent Scientific does
SeQuent Scientific Limited, now operating as Viyash Scientific Limited following its January 2026 rebranding, is an Indian-headquartered, publicly listed (NSE/BSE) integrated pharmaceutical enterprise built around four business verticals: Active Pharmaceutical Ingredients (API), Human Health finished dosage formulations, Animal Health products, and CDMO services. The company was founded in 1985, is headquartered in Hyderabad, and was historically backed by Carlyle Group. Its manufacturing footprint spans 15+ facilities across four continents with total reactor capacity of 2,300 KL+, multi-scale reactor capability from 100 L to 15 KL, and dedicated suites for high-potency APIs (HPAPI) and cytotoxic (OEB 4/5) products.
The technology platform emphasizes complex chemistry, custom synthesis, and regulatory-grade manufacturing, supported by LIMS-enabled digital quality systems, advanced analytical instrumentation, and 190+ filed patents. The company holds approvals from USFDA, EU-GMP, WHO GMP, EDQM, ANVISA, NMPA China, PMDA, MFDS Korea, COFEPRIS, TGA Australia, and Health Canada; in August 2024 it received WHO prequalification for its Albendazole API, enabling supply into UN agency global health programs. The combined entity is described as India's first and largest globally integrated animal health company and one of the Top 25 animal health companies globally.
The business model is B2B enterprise pharmaceutical manufacturing with quote-based, multi-year contracts. Revenue is generated through API sales, finished dosage formulation supply, veterinary pharmaceuticals, and CDMO services (custom synthesis and contract manufacturing). Customers are global pharmaceutical manufacturers; pricing is not publicly disclosed. In September 2024 SeQuent announced a strategic merger with Viyash Lifesciences valued at ₹8,000 crore; NCLT approved the merger in November 2025 and the combined entity was renamed Viyash Scientific Limited in January 2026, operating across 150+ countries with FY26 revenue of ₹34,203 million.
SeQuent Scientific firmographics
Firmographics- Name
- SeQuent Scientific
- Legal name
- Viyash Scientific Ltd.
- Website
- https://sequent.in
- Company type
- Public
- Founded year
- 1985
- Operating status
- Acquired
- Headcount range
- 1,001–5,000 employees
- Short description
- Viyash Scientific Limited (formerly SeQuent Scientific) is an Indian integrated pharmaceutical enterprise operating four verticals — API, Human Health formulations, Animal Health, and CDMO services — across 150+ countries, serving global pharmaceutical manufacturers from 15+ manufacturing facilities in India and abroad.
- Ownership category
- akta.pro rank
SeQuent Scientific industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industry
- Small-Molecule API Commercial Manufacturing (HLAGAHAB)
Keywords
Where SeQuent Scientific is headquartered
LocationHeadquarters
- HQ city
- Bangalore
- HQ country
- India
- HQ region
- Asia
Offices1 record
Markets served
SeQuent Scientific business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- API Manufacturing and Sales: Active Pharmaceutical Ingredients manufactured to highest global standards sold to pharmaceutical companies worldwide. Includes both Human API and Animal API products with regulatory-accredited manufacturing facilities.
- Human Health Formulations: End-to-end FDF (Finished Dosage Formulation) development and manufacturing including USFDA compliant facilities, ANDA filing, IP evaluation and pharmacovigilance services.
- Animal Health Products: Veterinary pharmaceuticals including animal health APIs and finished dosage formulations. India’s first & largest global integrated animal health company, among Top 25 animal companies globally.
- CDMO Services: Contract development and manufacturing organization services including custom synthesis, dedicated HPAPI/cytotoxic handling, and analytical support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise pharmaceutical products and services |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels2 records
SeQuent Scientific product offering
Product offeringCore offering
SeQuent Scientific is an integrated pharmaceutical enterprise that manufactures and sells Active Pharmaceutical Ingredients (APIs), finished dosage formulations for human and animal health, and provides contract development and manufacturing (CDMO) services. The company operates 15+ manufacturing facilities across four continents with a capacity of 2,300 KL+, supplying global pharmaceutical manufacturers and veterinary health companies. It is positioned among the Top 25 animal health companies globally and serves customers in over 150 countries.
Product overview
Viyash Scientific Ltd. (formerly SeQuent Scientific following the merger with Viyash Lifesciences) is an integrated pharmaceutical enterprise with four core business verticals: API (Active Pharmaceutical Ingredients), Human Health, Animal Health, and CDMO Services. The company operates across the pharmaceutical value chain from API manufacturing to finished dosage formulations, with manufacturing facilities across multiple continents serving customers in numerous countries.
Differentiator
Problem solved
Functional benefit
Products and services
- API (Active Pharmaceutical Ingredients) Active Pharmaceutical Ingredients manufactured to the highest global standards with regulatory accredited manufacturing facilities, multi-scale reactor capabilities (100 Liter to 15 KL), and manufacturing capacity of 2,300 KL+. Sold to pharmaceutical manufacturers worldwide for both human and animal applications.
- Human Health Formulations Comprehensive pharmaceutical solutions for improving human healthcare, including end-to-end Finished Dosage Formulation (FDF) development and manufacturing with USFDA compliant facilities, ANDA filing, IP evaluation, and pharmacovigilance services.
- Animal Health Products Veterinary pharmaceuticals ensuring animal wellness and productivity, including animal health APIs and finished dosage formulations. GMP approved facilities with strong R&D and quality control; products include parasiticides, anti-infectives, and specialty formulations.
- CDMO Services End-to-end contract development and manufacturing services offering custom synthesis capabilities, dedicated suite to handle OEB 4/5 products, dedicated block for HPAPI/cytotoxic APIs, and advanced analytical instrumentation for product development and characterization.
Companies that use SeQuent Scientific
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
SeQuent Scientific technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
SeQuent Scientific partnerships and signals
Strategic signalScale indicators13 records
Recent moves7 records
Expansion highlights6 records
SeQuent Scientific competitors and assessment
Company assessmentDirect peers
- Virbac: Global animal health company specializing in veterinary parasiticides, vaccines, and APIs with similar geographic spread; comparator on animal health end-market exposure.
- Phibro Animal Health: Global animal health pharmaceutical company with comparable parasiticide, anti-infective, and animal nutrition lines; one of the most direct comparables in the integrated animal health + API manufacturing space, similar size profile and geographic reach.
- Divi's Laboratories: Indian pure-play API and CDMO manufacturer with comparable multi-vertical small-molecule platform and global regulatory footprint (USFDA, EU-GMP); closest Indian peer on the human health API/CDMO side of the business.
- Dechra Pharmaceuticals: Specialty animal health company focused on veterinary APIs and formulations across companion and livestock species; direct peer in the animal pharma market and similar mid-cap profile.
- Jubilant Pharmova: Indian pharma company with CDMO services, API manufacturing, and radiopharmaceuticals; comparable on multi-site manufacturing, complex chemistry capability, and CDMO contract structure.
- Laurus Labs: Indian API and CDMO manufacturer with comparable small-molecule platform, multi-vertical product mix (ARV APIs, onco APIs, animal health), and emerging CDMO business; similar mid-cap growth profile.
Emerging players
- Neogen Corporation: Animal health and food safety company with veterinary pharmaceutical and diagnostic offerings; thematic peer in the animal health end-market with overlapping customer base (producers and veterinarians).
Broad incumbents
- Piramal Pharma: Indian pharma with significant CDMO services across complex APIs and HPAPI; comparable on contract manufacturing, regulated markets exposure, and integrated operating model.
- Zoetis: World's largest pure-play animal health company producing APIs, parasiticides, vaccines, and diagnostics; comparable end-markets (livestock + companion animal) and supply chain model, though significantly larger and brand-led.
- Aurobindo Pharma: Large Indian pharmaceutical company with substantial API manufacturing capacity and global finished dosage reach; comparable on scale, regulatory approvals, and integrated API + formulation model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SeQuent Scientific social profiles
Digital presenceSeQuent Scientific compliance and trust
Trust signalCompliance13 records
SeQuent Scientific financial estimates
Financial estimateRevenue estimate
Valuation estimate
SeQuent Scientific leadership team
Management profileNumber of profiles
Profiles1 record
SeQuent Scientific funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SeQuent Scientific M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SeQuent Scientific
What does SeQuent Scientific do?
SeQuent Scientific is an integrated pharmaceutical enterprise that manufactures and sells Active Pharmaceutical Ingredients (APIs), finished dosage formulations for human and animal health, and provides contract development and manufacturing (CDMO) services. The company operates 15+ manufacturing facilities across four continents with a capacity of 2,300 KL+, supplying global pharmaceutical manufacturers and veterinary health companies. It is positioned among the Top 25 animal health companies globally and serves customers in over 150 countries.
Is SeQuent Scientific a public or private company?
SeQuent Scientific is a public company. It is classified as public and is currently acquired.
When was SeQuent Scientific founded?
SeQuent Scientific was founded in 1985. It employs 1,001 to 5,000 people.
Where is SeQuent Scientific based?
SeQuent Scientific is headquartered in Bangalore, India, in the Asia region.
How does SeQuent Scientific make money?
Four revenue lines are on record. API Manufacturing and Sales are the primary driver. The others are human Health Formulations, animal Health Products and CDMO Services.
Who are SeQuent Scientific's main competitors?
Direct peers on record are Virbac, Phibro Animal Health, Divi's Laboratories, Dechra Pharmaceuticals, Jubilant Pharmova and Laurus Labs. Neogen Corporation is listed as an emerging player. Broad incumbents are Piramal Pharma, Zoetis and Aurobindo Pharma.
Does SeQuent Scientific have an API?
No public API is recorded for SeQuent Scientific.
What industry is SeQuent Scientific in?
SeQuent Scientific's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.